Department of Hematology Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Road, NE Building B, Suite 4302, Atlanta, GA 30322, USA.
Future Oncol. 2011 Jan;7(1):111-22. doi: 10.2217/fon.10.159.
Follicular lymphoma is an indolent lymphoma associated with a relapsing course. Immunization with tumor B cell idiotype (Id; a unique variable region of surface B cell immunoglobulin) may induce humoral and cellular immune response against the tumor. Based on promising results from early phase clinical trials with Id vaccine, three Phase III trials were initiated, which, despite failing to meet their primary end points, still provided a glimmer of optimism. This article describes the clinical development of the Id vaccine against follicular lymphoma, outlines the outcomes of clinical trials and delineates the future prospects for the integration of the idiotype vaccine into follicular lymphoma treatment.
滤泡性淋巴瘤是一种惰性淋巴瘤，与反复发作的病程相关。用肿瘤 B 细胞独特型（Id；表面 B 细胞免疫球蛋白的独特可变区）免疫接种可能会诱导针对肿瘤的体液和细胞免疫应答。基于 Id 疫苗早期临床试验的有希望的结果，启动了三项 III 期临床试验，尽管这些试验未能达到主要终点，但仍提供了一线希望。本文描述了针对滤泡性淋巴瘤的独特型疫苗的临床开发，概述了临床试验的结果，并阐明了将独特型疫苗纳入滤泡性淋巴瘤治疗的未来前景。
